Camurus’ R&D Receives Boost As Novartis Exercises Octreotide Option
This article was originally published in The Pink Sheet Daily
Executive Summary
The race to develop an easier-to-administer and less painful injection of octreotide for acromegaly is getting hotter, as Novartis takes over development of the Swedish company’s novel subcutaneous long-acting octreotide formulation.